Pharmaxis has one product available in market, called Aridol or Osmohale. It is approved throughout much of the world for identifying airway hyperresponsiveness, a hallmark of asthma.
Please contact your doctor if you wish to undertake an Aridol challenge test
Bronchitol is Pharmaxis' second product in development. It is currently completing final clinical trials in patients with bronchiectasis and cystic fibrosis.
Patients who may be eligible for compassionate access to Bronchitol, or participating in a trial, should contact their doctor.
Our work in respiratory diseases focuses on:
For information related to our products, clinical trials or medical research, contact:
Email: med.info@pharmaxis.com.au
Phone: +61 2 9454 7264
For reporting of any Adverse Events please email adverse.events@pharmaxis.com.au or fax +61 2 9454 7255
